Search

everythinglearnresearchcommunity

for

Search:↓

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

GHK-Cu is being discussed as a potential treatment for male pattern baldness. Users are sharing experiences and asking about its effectiveness and side effects.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

Taking potassium chloride and magnesium stopped minoxidil-induced palpitations. The user is considering continuing minoxidil with these supplements.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The conversation is about finding a legitimate source for Procyanidin B2 or Apple Extract with a clear percentage of Procyanidin B2 for making a topical solution. The user reports thicker and darker body hair after taking Oral Apple Polyphenols extract.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

User experienced dizziness on 1.25 mg of finasteride, reduced to 0.75 mg and felt better. They also use zinc, B complex, green tea extract, derma roll with caster oil, and nizol shampoo.

Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.

A user reported success with a once-a-day chewable pill containing Min 3mg, biotin 2.5mg, fin 1.1mg, vit B5 10mg, vit B6 2mg, and vit C 100mg for hair regrowth. They experienced no side effects and noticed healthier hair and more facial hair.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

The conversation is about using oral finasteride and minoxidil for hair loss, with consideration of adding topical GHK-Cu for skin and hair benefits. The user seeks opinions on this combination.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

Personal experience with Procyanidin B2 shows it's ineffective for hair loss. Viviscal Pro supplement tablets, containing Procyanidin B2, didn't help after 8 months of use.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

Switching from topical to an oral combo pill (1.2 mg finasteride, 3 mg minoxidil, vitamins) improved hair thickness without noticeable side effects. The user appreciates the convenience of a single daily pill over twice-daily topical applications.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

Hair loss treatments discussed include 200mg Spiro, bicalutamide, and finasteride. Endocrinologist advises against bicalutamide and finasteride due to potency and risks.

The user is experimenting with GHK-Cu and AHK-Cu to stop hair loss and promote hair growth, using a serum from Etsy and injectable GHK-Cu. They supplement this with dermastamping and ketoconazole shampoo.

N-Acetyl-Cysteine (NAC) is being explored for treating hair loss, but users report mixed results. Some also mention using Quercetin and Resveratrol without significant hair improvement.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user has been using 1mg finasteride and biotin-collagen supplements for 5 months, noticing some progress in hair regrowth. They also use various oils and shampoos, plan to start oral minoxidil, and seek advice on improving their hair care routine.